

Supplemental Appendix

The Clinical and Economic Burden of Hyperkalemia to Medicare and Commercial Payers

Kathryn Fitch, RN, MEd; J. Michael Woolley, PhD; Tyler Engel, ASA, MAAA; Helen Blumen, MD, MBA


This Appendix has not been edited and is provided as supplemental materials for this article, which was published in *American Health & Drug Benefits* in June 2017.

National Drug Codes for Sodium Polystyrene Sulfonate			
00024107501	00054380563	00904604127	46287000601
00054016550	00054881501	10702003615	46287000604
00054016551	00054881611	10702003645	46287000660
00054016555	00054881755	17856003615	46287001216
00054016563	00574200202	24987007501	49452694501
00054037950	00574200216	38779025808	49452694502
00054037951	00574200302	38779025809	49452694503
00054037955	00574200316	42806001396	51927190100
00054037963	00574200416	42808050016	54868443900

Note: The identification algorithm for sodium polystyrene sulfonate was:

- Generic product identifier (GPI) began with “9945” OR
- GPI began with “9678705070” OR
- Generic name contained “Kayexalate” OR
- Product name contained “polystyrene”

Identification of Hyperkalemia Patients by Claim Type



ED = emergency department; OP = outpatient; SPS = sodium polystyrene sulfonate.

Source: Milliman's analysis of 2014 Medicare 5% sample data and MarketScan medical claims data.